Skip to main content

Table 6 Demographics, clinical characteristics, and treatments of GC/GEJC/EAC patients according to de novo or recurrent disease

From: Global retrospective analysis of clinician- and patient-reported clinical characteristics and humanistic burden of patients with gastroesophageal cancers on first-line treatment

 

Total

De novo

Recurrent

Age, years

682

552

130

 Mean (SD)

64.6 (10.0)

65.6 (9.8)

60.3 (9.6)

 Median (IQR)

66 (59–71)

67 (60–72)

62 (55–68)

Confirmed diagnosis, n (%)

682

552

130

 GC

415 (60.9)

324 (58.7)

91 (70.0)

 GEJC

192 (28.2)

162 (29.4)

30 (23.1)

 EAC

75 (11.0)

66 (12.0)

9 (6.9)

Time since diagnosis, months

625

502

123

 Mean (SD)

6.3 (13.0)

3.6 (4.7)

17.6 (24.8)

 Median (IQR)

3 (2–6)

2 (2–4)

13 (7–20)

Time since advanced diagnosis, months

629

503

126

 Mean (SD)

4.8 (7.6)

3.6 (4.7)

9.5 (13.2)

 Median (IQR)

3 (2–5)

3 (2–4)

5 (3–11)

Nonpharmacological treatments, n (%)

682

552

130

 Surgery

162 (23.8)

75 (13.6)

87 (66.9)

 Radiotherapy

103 (15.1)

70 (12.7)

33 (25.8)

 Stent

72 (10.6)

61 (11.1)

11 (8.5)

 Laser therapy

5 (0.7)

5 (0.9)

0 (0.0)

 None

400 (58.7)

382 (69.2)

18 (13.9)

Side effect experienced (> 10%), n (%)

296 (45.0)

210 (39.3)

86 (69.4)

 Nausea

186 (62.8)

128 (61.0)

58 (67.4)

 Fatigue

144 (48.7)

98 (46.7)

46 (53.5)

 Anemia

106 (35.8)

72 (34.3)

34 (39.5)

 Loss of appetite

103 (34.8)

62 (29.5)

41 (47.7)

 Vomiting

97 (32.8)

52 (24.8)

45 (52.3)

 Low white blood cell count

86 (29.1)

59 (28.1)

27 (31.4)

 Diarrhea

81 (27.4)

61 (29.1)

20 (23.3)

 Weight loss/gain

66 (22.3)

35 (16.7)

31 (36.1)

 Low platelet count

59 (19.9)

38 (18.1)

21 (24.4)

 Numbness in hands and feet

56 (18.9)

38 (18.1)

18 (20.93)

 Hair loss/thinning

54 (18.2)

27 (12.9)

27 (31.4)

 Abdominal pain

30 (10.1)

15 (7.1)

15 (17.4)

Bothered by side effects, n (%)

676

550

126

 Not at all

81 (12.0)

68 (12.4)

13 (10.3)

 A little bit

212 (31.4)

180 (32.7)

32 (25.4)

 Somewhat

247 (36.5)

191 (34.7)

56 (44.4)

 Quite a bit

110 (16.3)

89 (16.2)

21 (16.7)

 Very much

26 (3.5)

22 (4.0)

4 (3.2)

EQ-5D-3L utility index

672

544

128

 Mean (SD)

0.70 (0.29)

0.69 (0.29)

0.77 (0.24)

 Median (IQR)

0.78 (0.59–0.93)

0.76 (0.55–0.89)

0.89 (0.70–0.94)

EQ-VAS

675

550

125

 Mean (SD)

58.1 (19.8)

58.4 (20.2)

56.6 (18.1)

 Median (IQR)

60 (45–75)

60 (45–75)

60 (47–70)

FACT: Gastric cancer subscale

677

549

128

 Mean (SD)

40.9 (14.2)

41.4 (14.5)

39.0 (12.6)

 Median (IQR)

41 (31–51)

41 (32–52)

38 (31–48)

FACT: Trial outcome index

602

489

113

 Mean (SD)

68.0 (23.6)

68.8 (24.4)

64.4 (19.4)

 Median (IQR)

68 (53–84)

69 (54–86)

65 (53–77)

FACT-G

296

244

52

 Mean (SD)

56.9 (16.8)

57.5 (17.5)

54.4 (13.0)

 Median (IQR)

54 (47–67)

55 (48–69)

53 (45–62)

FACT: Gastric total

281

230

51

 Mean (SD)

100.3 (28.9)

101.2 (30.1)

96.4 (22.6)

 Median (IQR)

97 (82–121)

98 (83–123)

97 (81–111)

  1. EAC Esophageal adenocarcinoma, EQ-5D-3L EuroQol 5-Dimension 3-Level questionnaire, EQ-VAS EuroQol—Visual Analogue Scale, FACT Functional Assessment of Cancer Therapy, FACT-G Functional Assessment of Cancer Therapy – General, FACT-Ga Functional Assessment of Cancer Therapy—Gastric Cancer, GC Gastric cancer, GEJC Gastroesophageal junction cancer, HER2 Human epidermal growth factor receptor 2, IQR Interquartile range, SD Standard deviation